Hyperion Therapeutics Receives Orphan Drug Designation for HPN-100 for theTreatment of Urea Cycle Disorders
Tue, 05/05/2009 - 4:42am
Hyperion Therapeutics,Inc. has announced that HPN-100 has received orphan product designation fromthe FDA for maintenance treatment of patientswith enzymes of the urea cycle. The company recently announced results fromits phase II study and intends to initiate a phase III clinical program inthis indication in the second half of 2009.